Lymphoma and Multiple Myeloma

Patients will be randomized to one of the following two treatment arms:

Arm A: Lenalidomide Alone
The starting dose of lenalidomide will be 15 mg/day PO on days 1-21 followed by 7 days of rest. After cycle 2, the dose will be escalated in patients who have not had therapy delayed and who have recovered from previous toxicity. Maximum dose will be 25 mg/day. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of twelve cycles.

Arm B: Rituximab + Lenalidomide
Lenalidomide will be administered same as stated in Arm A. Rituximab will be administered at a dose of 375 mg/m2 by IV on Days 8, 5, 22 and 29 beginning one week after initiation of lenalidomide. Patients will receive four weekly infusions of rituximab, and twelve cycles of lenalidomide.

Restaging for both Arms will be during months 2, 4, 6, 9, 12, 15, 18, and 24, and then yearly until disease progression or for a maximum of ten years from study entry.

Patients will be randomized to one of two treatment arms:
Arm A - Patients will receive R-CHOP Chemotherapy
Arm B - Patients receive dose-adjusted EPOCH-R Chemotherapy

Adult subjects with histologic diagnosis of diffuse large B-cell lymphoma who have progressed or relapsed since the most receive therapy. Subjects must have received at least one prior combination chemotherapy regimen.
There is no limit on the number of prior therapies.

Histologically confirmed mantle cell or diffuse large B-cell lymphoma receiving at least one prior systemic therapy. DLBCL patients are not eligible if they received bortezomib.

Patients will receive: Vorinostat 400 mg (total daily dose as a single dose) on days 1-5 and 8-12. Bortezomib 1.3 mg/m2/d IV on days 1, 4, 8, and 11.

Regimen is repeated every 3 weeks.

Patients who experience a complete or partial response following at least one year of treatment may go off study treatment but remain on study and resume study treatment upon disease progression if the study remains open.

hLL1 (humanized anti-CD74 monoclonal antibody) administered intravenously daily, five days
per week (Monday to Friday), for two weeks at one of 4 planned dose levels. Treatment occurs over 2 weeks
with post-treatment evaluations over 12 weeks. Follow-up is required in all patients until resolution of any treatment related abnormalities or until relapse occurs.

CLL patients who are refractory to or relapsed after at least 2 prior therapies, including fludarabine, alone or in combination.

Patients must be symptomatic.

The study drug should be taken twice a day. The patient should take the morning dose with water on an empty stomach; food can be consumed at least an hour after dosing. The evening dose should be taken with water approximately 12 hours after the morning dose and at least 2 hours after a meal.

Each patient will be assessed for clinical response after completing 1 cycle of 28 days of treatment. Treatment may continue for up to a total of 6 cycles.

Patients must have histologically proven relapsed or refractory MCL, DLBCL including subtypes mediastinal large B cell, centroblastic, immunoblastic, T-cell rich B- cell and anaplastic large B-cell lymphoma, or low grade B-cell NHL.

Bortezomib is administered to Patients twice weekly, with the first dose being given two days prior to the treatment dose of 131I-Tositumomab, and the second dose two days after Radioimmunotherapy (RIT) for a total of 5 doses.